Loading
Patients with primary mediastinal B-cell lymphoma whose PET scan was negative after immunochemotherapy did just as well without consolidation radiotherapy as with it, so radiotherapy can safely be omitted for them.
Phase 3 non-inferiority trial of 545 patients with primary mediastinal B-cell lymphoma treated with rituximab-containing immunochemotherapy; the 268 with a complete metabolic response on PET were randomised to observation or consolidation mediastinal radiotherapy.
Thirty-month progression-free survival was 96.2 percent with observation and 98.5 percent with radiotherapy, meeting non-inferiority, with overall survival of 99 percent in both arms.
End-of-treatment PET now decides radiotherapy in primary mediastinal B-cell lymphoma: a negative scan means no radiotherapy, whichever chemotherapy regimen was used.
Shares Primary mediastinal (thymic) large B-cell lymphoma, Journal of Clinical Oncology.
Shares IELSG37, Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy, Primary mediastinal (thymic) large B-cell lymphoma.
Shares IELSG37, Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy, Primary mediastinal (thymic) large B-cell lymphoma.
Shares Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy, Primary mediastinal (thymic) large B-cell lymphoma.
Shares IELSG37, Primary mediastinal (thymic) large B-cell lymphoma.
Shares Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy, Primary mediastinal (thymic) large B-cell lymphoma.
Shares IELSG37, Primary mediastinal (thymic) large B-cell lymphoma.